Madrigal Pharmaceuticals (MDGL) Revenue (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Revenue of $364.3 million for Q2 2026, up 71.17% year-over-year from $212.8 million in Q2 2025, and up 17.0% quarter-over-quarter from $311.3 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Revenue (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Revenue for 6 consecutive years, with $364.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Revenue rose 71.17% year-over-year to $364.3 million; the TTM figure through Jun 2026 stood at $1.3 billion (up 149.04% YoY), while the FY2025 annual figure was $958.4 million, up 432.05% from the prior year.
- Revenue grew to $364.3 million in Q2 2026 per MDGL's latest filing, from $311.3 million in the prior quarter.
- Across five years, Revenue topped out at $364.3 million in Q2 2026 and bottomed at $14.6 million in Q2 2024.
- Historically, Revenue has averaged $201.6 million across 3 years, with a median of $212.8 million in 2025.
- Annual changes were most pronounced in 2025 — Revenue jumped 1353.76% — and 2026, when it surged 71.17%.
- Madrigal Pharmaceuticals' Revenue stood at $103.3 million in 2024, then surged by 210.77% to $321.1 million in 2025, then increased by 13.44% to $364.3 million in 2026.
- Business Quant data shows MDGL's Revenue at $364.3 million in Q2 2026, $311.3 million in Q1 2026, and $321.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 364.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 364.25 Mn |
| Mar 31, 2026 | 311.34 Mn |
| Dec 31, 2025 | 321.08 Mn |
| Sep 30, 2025 | 287.27 Mn |
| Jun 30, 2025 | 212.80 Mn |
| Mar 31, 2025 | 137.25 Mn |
| Dec 31, 2024 | 103.32 Mn |
| Sep 30, 2024 | 62.18 Mn |
| Jun 30, 2024 | 14.64 Mn |
| Sep 30, 2012 | 147,000.00 |
| Jun 30, 2012 | 147,000.00 |
| Mar 31, 2012 | 147,000.00 |
| Dec 31, 2011 | 121,000.00 |
| Sep 30, 2011 | 1.66 Mn |
| Jun 30, 2011 | 211,000.00 |
| Mar 31, 2011 | 1.14 Mn |
| Dec 31, 2010 | 4.04 Mn |
| Sep 30, 2010 | 3.38 Mn |
| Jun 30, 2010 | 3.36 Mn |